Beam Therapeutics Executive Sells Shares
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 01 2026
0mins
Should l Buy BEAM?
Source: Fool
- Executive Sale Details: Bethany J. Cavanagh, SVP of Finance at Beam Therapeutics, executed an open-market sale of 6,198 shares on January 22, 2026, valued at approximately $216,933, indicating a significant reduction in her stake in the company.
- Holding Proportion Analysis: The 6,198 shares sold represented 15.11% of Cavanagh's direct holdings at the time, a notably larger proportion than her recent median sell transactions, suggesting a material decrease in her exposure to the company's stock.
- Trading Plan Context: This transaction was conducted under a Rule 10b5-1 trading plan, which allows insiders to pre-arrange stock sales, reflecting a strategic decision by Cavanagh to manage her investment risk effectively.
- Company Financial Overview: Beam Therapeutics reported a total revenue of $55.70 million and a net loss of $414.64 million for 2026, and while the stock increased approximately 11% in 2025, the company continues to operate with negative net margins, prompting investors to closely monitor the progress of its drug candidates throughout the year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BEAM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BEAM
Wall Street analysts forecast BEAM stock price to rise
13 Analyst Rating
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 27.620
Low
21.00
Averages
42.00
High
80.00
Current: 27.620
Low
21.00
Averages
42.00
High
80.00
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Beam Therapeutics Stock Soars to New Heights
- Surpassing Market Expectations: Beam Therapeutics reported a loss of $0.10 per share, significantly better than the expected loss of $0.99, while revenue reached $114.11 million, far exceeding the forecast of $12.567 million, indicating robust performance in genetic medicine.
- Financial Backing: The company announced a $500 million senior secured credit facility, with $100 million funded at close and an additional $300 million available upon achieving specific clinical and regulatory milestones, providing strong financial support for future growth.
- New Drug Application Plans: Beam plans to file an Investigational New Drug (IND) application for BEAM-304 with the FDA in 2026, aimed at treating phenylketonuria, further expanding its liver-targeted genetic disease portfolio and demonstrating ongoing commitment to innovative drug development.
- Share Price Surge: As of Tuesday, Beam Therapeutics shares rose by 13.55% to $32.17, reflecting strong market confidence in the company's growth potential and solidifying its leadership position in the gene therapy sector.
See More
Beam Therapeutics Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Report: Beam Therapeutics reported a Q4 GAAP EPS of $2.33 and revenue of $114.1 million, representing a remarkable 279.4% year-over-year increase, highlighting the company's robust growth potential in the precision genetic medicine sector.
- Financial Stability: The company anticipates that its cash, cash equivalents, and marketable securities as of December 31, 2025, along with a minimum $200 million drawdown from the Sixth Street facility, will sufficiently cover operating expenses and capital expenditures through mid-2029, ensuring financial stability for the coming years.
- Product Development Progress: Beam plans to launch risto-cel for sickle cell disease (SCD), execute the pivotal BEAM-302 development plan for AATD, and conduct clinical proof of concept for BEAM-304 in PKU, demonstrating a strategic focus across multiple therapeutic areas.
- Positive Market Reaction: Following advancements in precision genetic therapies and strategic plans for 2026, Beam Therapeutics' shares surged, reflecting investor confidence in the company's future growth prospects.
See More
Beam Therapeutics Executive Sells Shares
- Executive Sale Details: Bethany J. Cavanagh, SVP of Finance at Beam Therapeutics, executed an open-market sale of 6,198 shares on January 22, 2026, valued at approximately $216,933, indicating a significant reduction in her stake in the company.
- Holding Proportion Analysis: The 6,198 shares sold represented 15.11% of Cavanagh's direct holdings at the time, a notably larger proportion than her recent median sell transactions, suggesting a material decrease in her exposure to the company's stock.
- Trading Plan Context: This transaction was conducted under a Rule 10b5-1 trading plan, which allows insiders to pre-arrange stock sales, reflecting a strategic decision by Cavanagh to manage her investment risk effectively.
- Company Financial Overview: Beam Therapeutics reported a total revenue of $55.70 million and a net loss of $414.64 million for 2026, and while the stock increased approximately 11% in 2025, the company continues to operate with negative net margins, prompting investors to closely monitor the progress of its drug candidates throughout the year.
See More
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
BEAM Options Analysis: Put Contract Offers 11.29% YieldBoost
- Put Contract Yield: Selling a put contract at a $31.00 strike price allows investors to collect a $3.50 premium, effectively lowering their cost basis to $27.50, which represents a 9% discount to the current stock price of $34.19, making it an attractive option for potential BEAM investors.
- Expiration Risk Analysis: Current data indicates a 63% chance that the put contract will expire worthless, which would yield an 11.29% return on cash commitment, or an annualized 43.86%, highlighting the potential appeal of this investment strategy.
- Call Contract Yield: Selling a call contract at a $35.00 strike price while purchasing BEAM shares at $34.19 allows investors to collect a $3.50 premium, leading to a total return of 12.61% if the stock is called away at expiration, providing an additional profit opportunity for investors.
- Market Volatility: The implied volatility for the put contract is 101%, while for the call contract it is 105%, indicating market expectations for future price fluctuations of BEAM stock, with an actual trailing twelve-month volatility of 77%, offering crucial risk assessment insights for investors.
See More
Beam Therapeutics Stock Soars to New Heights
- Surpassing Market Expectations: Beam Therapeutics reported a loss of $0.10 per share, significantly better than the expected loss of $0.99, while revenue reached $114.11 million, far exceeding the forecast of $12.567 million, indicating robust performance in genetic medicine.
- Financial Backing: The company announced a $500 million senior secured credit facility, with $100 million funded at close and an additional $300 million available upon achieving specific clinical and regulatory milestones, providing strong financial support for future growth.
- New Drug Application Plans: Beam plans to file an Investigational New Drug (IND) application for BEAM-304 with the FDA in 2026, aimed at treating phenylketonuria, further expanding its liver-targeted genetic disease portfolio and demonstrating ongoing commitment to innovative drug development.
- Share Price Surge: As of Tuesday, Beam Therapeutics shares rose by 13.55% to $32.17, reflecting strong market confidence in the company's growth potential and solidifying its leadership position in the gene therapy sector.
See More
Beam Therapeutics Reports Q4 Earnings Exceeding Expectations
- Strong Earnings Report: Beam Therapeutics reported a Q4 GAAP EPS of $2.33 and revenue of $114.1 million, representing a remarkable 279.4% year-over-year increase, highlighting the company's robust growth potential in the precision genetic medicine sector.
- Financial Stability: The company anticipates that its cash, cash equivalents, and marketable securities as of December 31, 2025, along with a minimum $200 million drawdown from the Sixth Street facility, will sufficiently cover operating expenses and capital expenditures through mid-2029, ensuring financial stability for the coming years.
- Product Development Progress: Beam plans to launch risto-cel for sickle cell disease (SCD), execute the pivotal BEAM-302 development plan for AATD, and conduct clinical proof of concept for BEAM-304 in PKU, demonstrating a strategic focus across multiple therapeutic areas.
- Positive Market Reaction: Following advancements in precision genetic therapies and strategic plans for 2026, Beam Therapeutics' shares surged, reflecting investor confidence in the company's future growth prospects.
See More
Beam Therapeutics Executive Sells Shares
- Executive Sale Details: Bethany J. Cavanagh, SVP of Finance at Beam Therapeutics, executed an open-market sale of 6,198 shares on January 22, 2026, valued at approximately $216,933, indicating a significant reduction in her stake in the company.
- Holding Proportion Analysis: The 6,198 shares sold represented 15.11% of Cavanagh's direct holdings at the time, a notably larger proportion than her recent median sell transactions, suggesting a material decrease in her exposure to the company's stock.
- Trading Plan Context: This transaction was conducted under a Rule 10b5-1 trading plan, which allows insiders to pre-arrange stock sales, reflecting a strategic decision by Cavanagh to manage her investment risk effectively.
- Company Financial Overview: Beam Therapeutics reported a total revenue of $55.70 million and a net loss of $414.64 million for 2026, and while the stock increased approximately 11% in 2025, the company continues to operate with negative net margins, prompting investors to closely monitor the progress of its drug candidates throughout the year.
See More
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
See More
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
- AI Infrastructure Boost: ARK Invest increased positions in semiconductor companies like AMD, Broadcom, and TSMC, signaling strong confidence in the infrastructure for AI workloads, which is expected to drive long-term growth for these firms.
- Gene Editing Investments: The firm added 196K shares of Intellia Therapeutics and 49K shares of 10x Genomics, continuing to focus on next-generation sequencing and in vivo gene editing, aiming to capture innovative opportunities in the biotech sector.
- Autonomous Driving Focus: ARK invested in companies like WeRide and Pony AI in the autonomous driving and robotics space, reinforcing its strategic positioning in future transportation technologies, which is likely to enhance portfolio diversity and potential returns.
- Trimmed Mature Tech Holdings: ARK sold over 86K shares of Tesla worth more than $37 million and reduced stakes in Unity Software, reflecting a cautious stance on mature tech companies that may impact short-term stock performance.
See More
BEAM Options Analysis: Put Contract Offers 11.29% YieldBoost
- Put Contract Yield: Selling a put contract at a $31.00 strike price allows investors to collect a $3.50 premium, effectively lowering their cost basis to $27.50, which represents a 9% discount to the current stock price of $34.19, making it an attractive option for potential BEAM investors.
- Expiration Risk Analysis: Current data indicates a 63% chance that the put contract will expire worthless, which would yield an 11.29% return on cash commitment, or an annualized 43.86%, highlighting the potential appeal of this investment strategy.
- Call Contract Yield: Selling a call contract at a $35.00 strike price while purchasing BEAM shares at $34.19 allows investors to collect a $3.50 premium, leading to a total return of 12.61% if the stock is called away at expiration, providing an additional profit opportunity for investors.
- Market Volatility: The implied volatility for the put contract is 101%, while for the call contract it is 105%, indicating market expectations for future price fluctuations of BEAM stock, with an actual trailing twelve-month volatility of 77%, offering crucial risk assessment insights for investors.
See More
